What do systematic reviews say?

Mycophenolate mofetil vs methotrexate

Mycophenolate mofetil showed no clear difference in incidence of relapse compared with methotrexate (low certainty).

• Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic… 2014 · Cochrane Headline outcomes only
  RR 0.84 [0.52, 1.38]
  2 studies · 129 participants
  Low

Mycophenolate mofetil vs methotrexate

Mycophenolate mofetil showed no clear difference in nonrelapse mortality compared with methotrexate (low certainty).

• Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic… 2014 · Cochrane Headline outcomes only
  RR 1.21 [0.62, 2.36]
  1 study · 89 participants
  Low

Mycophenolate mofetil vs methotrexate

Mycophenolate mofetil showed no clear difference in prevention of chronic GVHD compared with methotrexate (low certainty).

• Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic… 2014 · Cochrane Headline outcomes only
  RR 0.92 [0.65, 1.3]
  2 studies · 129 participants
  Low

Mycophenolate mofetil vs methotrexate

Mycophenolate mofetil may leads to lower incidence of severe mucositis compared with methotrexate (low certainty).

• Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic… 2014 · Cochrane Headline outcomes only
  RR 0.48 [0.32, 0.73]
  3 studies · 174 participants
  Low

Mycophenolate mofetil vs methotrexate

Mycophenolate mofetil may leads to lower use of total parenteral nutrition compared with methotrexate (low certainty).

• Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic… 2014 · Cochrane Headline outcomes only
  RR 0.48 [0.26, 0.91]
  2 studies · 129 participants
  Low

Mycophenolate mofetil vs methotrexate

Mycophenolate mofetil may leads to lower incidence of narcotic use for pain control compared with methotrexate (low certainty).

• Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic… 2014 · Cochrane Headline outcomes only
  RR 0.76 [0.63, 0.91]
  2 studies · 129 participants
  Low

Eculizumab vs placebo

• Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 87 participants
  GRADE not reported

Eculizumab vs placebo

• Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 87 participants
  GRADE not reported

Eculizumab vs placebo

• Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 87 participants
  Low

Eculizumab vs placebo

• Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 87 participants
  Moderate

Eculizumab vs placebo

Eculizumab showed no clear difference in adverse events (serious and nonserious) Medical Dictionary for… compared with placebo (low certainty).

• Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria 2014 · Cochrane Headline outcomes only
  RR 0.45 [0.15, 1.37]
  1 study · 87 participants
  Low

Eculizumab vs placebo

Eculizumab probably leads to higher transfusion independence compared with placebo (moderate certainty).

• Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria 2014 · Cochrane Headline outcomes only
  RR 46.02 [2.88, 735.53]
  1 study · 87 participants
  Moderate

Eculizumab vs placebo

Eculizumab probably leads to lower withdrawal for any reason compared with placebo (moderate certainty).

• Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria 2014 · Cochrane Headline outcomes only
  RR 0.2 [0.05, 0.88]
  1 study · 87 participants
  Moderate

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

First‐line allogeneic hematopoietic stem cell transplantation of… showed no clear difference in overall mortality compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin (low certainty).

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  HR 0.95 [0.45, 1.91]
  3 studies · 203 participants
  Low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 54 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 54 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 35 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 52 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

First‐line allogeneic hematopoietic stem cell transplantation of… showed no clear difference in secondary clonal disease or malignancies compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin (low certainty).

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  Peto OR 0.54 [0.07, 4]
  2 studies · 170 participants
  Low